Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile (CoronaVarCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05593042
Recruitment Status : Recruiting
First Posted : October 25, 2022
Last Update Posted : January 13, 2023
Sponsor:
Collaborator:
Sinovac Life Sciences Co., Ltd.
Information provided by (Responsible Party):
Pontificia Universidad Catolica de Chile

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Phase 2 clinical trial in adults previously vaccinated against SARS-CoV-2 in Chile with an initial schedule of two doses of CoronaVac® plus two booster doses with different vaccines. Subjects will randomly receive a third booster dose with Omicron, trivalent, or CoronaVac® vaccine. The humoral immunogenicity against COVID-19 will be compared in subjects that received the Omicron or the Trivalent vaccines with subjects that received CoronaVac® to determine the superiority of the two candidate vaccines versus CoronaVac®. Subjects will be followed for 6 months after the booster dose administration.

Condition or disease Intervention/treatment Phase
COVID-19 Vaccines Biological: CoronaVac® Biological: Omicron Vaccine Biological: Trivalent Vaccine Phase 2

Detailed Description:

This study will be a phase 2 randomized, double-blind, multicenter clinical trial in fully vaccinated adults, males, and females, who have previously received an initial schedule of two doses of CoronaVac® plus two booster doses with different vaccines against SARS-CoV-2 in Chile. Two groups of participants will be included: Heterologous group: subjects who had received two booster doses with mRNA or viral vector-based vaccine); and homologous group: subjects who have received two booster doses of CoronaVac® in a previous clinical trial (CoronaVac03CL).

Subjects of the heterologous group will randomly receive a booster dose with Omicron, trivalent, or CoronaVac® vaccine. On the other hand, subjects of the homologous group will randomly receive a booster dose of Omicron or trivalent vaccine.

The humoral immunogenicity against COVID-19 will be compared in subjects of the heterologous group that will receive Omicron or trivalent vaccine with subjects that will receive CoronaVac®, to determine the superiority of the two candidate vaccines versus CoronaVac®.

Subjects will be followed for 6 months after the booster dose administration.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 826 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: A specialized company designed the randomization algorithm of vaccines (IRT algorithm). The algorithm was designed considering the vaccination schedule of the subjects and the number of subjects assigned to each center. Once randomized, each participant will be assigned to a treatment branch/group. Neither the personnel administering it nor the rest of the team nor the participant will know which product was administered.
Primary Purpose: Prevention
Official Title: Phase 2, Randomized, Double-blind Study to Evaluate Immunogenicity Superiority of a Booster Dose With an Omicron or a Trivalent Vaccine Compared to CoronaVac, in Adults Immunized With Different Vaccine Schedules Against SARS-CoV-2 in Chile
Actual Study Start Date : November 28, 2022
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : September 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Heterologous group receiving CoronaVac®
General population that received two doses of CoronaVac® as a primary schedule of vaccination and two booster doses as part of the national vaccination schedule with mRNA or viral vector-based vaccines; and who receive a booster dose of CoronaVac®
 Biological: CoronaVac®
The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in pre-load syringes (0.5 mL) with 600 SU/0.5mL of inactivated SARS-CoV-2.
Other Name: Inactivated SARS-CoV-2 Vaccine (Vero Cells) - Sinovac
Experimental: Heterologous group receiving Omicron vaccine
General population that received two doses of CoronaVac® as a primary schedule of vaccination and two booster doses as part of the national vaccination schedule with mRNA or viral vector-based vaccines; and who receive a booster dose of Omicron vaccine
 Biological: Omicron Vaccine

An experimental intervention consisting of a booster dose of an inactivated Omicron variant vaccine.

The active ingredient is the SARS-CoV-2 virus (Omicron variant) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, packed in a pre-load syringe, and contains one dose (0.5mL) of 1200 SU of inactivated SARS-CoV-2 Omicron variant.
Experimental: Heterologous group receiving a trivalent vaccine
General population that received two doses of CoronaVac® as a primary schedule of vaccination and two booster doses as part of the national vaccination schedule with mRNA or viral vector-based vaccines; and who receive a booster dose of trivalent vaccine
 Biological: Trivalent Vaccine

An experimental intervention consisting of a booster dose of an inactivated trivalent (CZ02 strain, ancestral, Delta, and Omicron variants) variant vaccine.

The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral, Delta, and Omicron variants) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in a pre-load syringe containing one dose (0.5mL) (1200 SU of inactivated SARS-CoV-2 WT, 1200 SU of inactivated SARS-CoV-2 Delta variant, and 1200 SU of inactivated SARS-CoV-2 Omicron variant).
Experimental: Homologous group receiving Omicron vaccine
Participants of the CoronaVac03CL study who have received the primary regimen and two booster doses with CoronaVac® vaccine; and who receive a booster dose of Omicron vaccine
 Biological: Omicron Vaccine

An experimental intervention consisting of a booster dose of an inactivated Omicron variant vaccine.

The active ingredient is the SARS-CoV-2 virus (Omicron variant) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, packed in a pre-load syringe, and contains one dose (0.5mL) of 1200 SU of inactivated SARS-CoV-2 Omicron variant.
Experimental: Homologous group receiving a trivalent vaccine
Participants of the CoronaVac03CL study who have received the primary regimen and two booster doses with CoronaVac® vaccine and who receive a booster dose of trivalent vaccine
 Biological: Trivalent Vaccine

An experimental intervention consisting of a booster dose of an inactivated trivalent (CZ02 strain, ancestral, Delta, and Omicron variants) variant vaccine.

The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral, Delta, and Omicron variants) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in a pre-load syringe containing one dose (0.5mL) (1200 SU of inactivated SARS-CoV-2 WT, 1200 SU of inactivated SARS-CoV-2 Delta variant, and 1200 SU of inactivated SARS-CoV-2 Omicron variant).


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Superiority in humoral immunogenicity of the neutralizing antibodies against the Delta and Omicron variants in response to a booster dose of the trivalent vaccine compared to CoronaVac® in adults previously immunized against SARS-CoV-2. [ Time Frame: Up until 6 months after intervention ]
    Differences in the humoral immunogenicity (GMT ratio >1) of the neutralizing antibodies against the Delta and Omicron variants in response to a booster dose of the trivalent vaccine compared to CoronaVac® in adults who have initially received two doses of CoronaVac® and two booster doses with vaccines against SARS-CoV-2 different from CoronaVac® (mRNA or viral vectors (heterologous group)) will be evaluated.

  2. Superiority in humoral immunogenicity of neutralizing antibodies against the Omicron variant in response to a booster dose with the Omicron vaccine when compared with CoronaVac® in adults previously immunized against SARS-CoV-2. [ Time Frame: Up until 6 months after intervention ]
    Differences in the humoral immunogenicity (GMT ratio >1) of the neutralizing antibodies against the Omicron variant generated in response to a booster dose with the Omicron vaccine when compared with CoronaVac® in adults who have initially received two doses of CoronaVac® and two booster doses with vaccines against SARS-CoV-2 different from CoronaVac® (mRNA or viral vectors (heterologous group)) will be evaluated.

  3. Non-inferiority of neutralizing antibodies against the Omicron and Delta variants generated by a booster dose of trivalent vaccine when compared to CoronaVac® in adults previously immunized against SARS-CoV-2 in a heterologous schedule. [ Time Frame: Up until 6 months after intervention ]
    Evaluation of the non-inferiority (seroconversion rate ≥5%) of neutralizing antibodies against the Omicron and Delta variants generated by a booster dose of trivalent vaccine when compared to CoronaVac® in adults who have initially received two doses of CoronaVac® and two booster doses with vaccines from other platforms (mRNA or viral vectors (heterologous group)).

  4. Non-inferiority of neutralizing antibodies against the Omicron variant generated by a booster dose with Omicron vaccine when compared with CoronaVac® in adults previously immunized against SARS-CoV-2 in a heterologous schedule. [ Time Frame: Up until 6 months after intervention ]
    Evaluation of the non-inferiority (seroconversion rate ≥5%) of neutralizing antibodies against the Omicron variant generated by a booster dose with Omicron vaccine when compared with CoronaVac® in adults who have two doses of CoronaVac® and two booster doses with vaccines from other platforms (mRNA or viral vectors (heterologous group)).


Secondary Outcome Measures :
  1. Frequency of adverse events within the 7 and 28 days after the administration of a booster dose of Omicron, trivalent or CoronaVac® vaccines. [ Time Frame: 28 days after intervention ]
    Evaluate whether there are differences in the frequency of adverse events within the 7 and 28 days after the administration of a booster dose of Omicron, trivalent or CoronaVac® vaccines.

  2. Serious adverse events (SAE) and adverse events of special interest (AESI) in participants who received a booster dose of the Omicron, trivalent, or CoronaVac® vaccines. [ Time Frame: Up until 6 months after intervention ]
    Follow up of serious adverse events (SAE) and adverse events of special interest (AESI) will be performed for participants who received a booster dose of the Omicron, trivalent, or CoronaVac® vaccines.

  3. Humoral immunogenicity against the ancestral strain induced by a booster dose with Omicron vaccine or trivalent vaccine in adults previously immunized against SARS-CoV-2 in a heterologous schedule. [ Time Frame: Up until 6 months after intervention ]
    Evaluation of the humoral immunogenicity (GMT and seroconversion rate of neutralizing antibodies) against the ancestral strain, induced by a booster dose with Omicron vaccine or trivalent vaccine in adults who have two doses of CoronaVac® and two booster doses with vaccines from other platforms (mRNA or viral vectors (heterologous group)).

  4. Humoral immunogenicity induced by a booster dose with Omicron or trivalent vaccine in adults previously immunized against SARS-CoV-2 in a homologous schedule. [ Time Frame: Up until 6 months after intervention ]
    To evaluate the humoral immunogenicity (GMT and seroconversion of neutralizing antibodies) induced by a booster dose with Omicron or trivalent vaccine in adults who have previously received four doses of CoronaVac® (homologous group) against the ancestral strain, the Omicron, and Delta variants.

  5. Cellular immunogenicity generated, in a subgroup of participants, by the administration of a booster dose with Omicron, trivalent or CoronaVac® vaccines against the ancestral strain, the Omicron and Delta variants. [ Time Frame: Up until 6 months after intervention ]
    To evaluate, in a subgroup of participants, the cellular immunogenicity (T cell activation and cytokines secretion) generated by the administration of a booster dose with Omicron, trivalent or CoronaVac® vaccines against the ancestral strain, the Omicron and Delta variants.

  6. Levels of neutralizing antibodies -and in a subgroup of subjects, the cellular immunity- against the ancestral, Omicron and Delta strains at 6 months after the intervention. [ Time Frame: 6 months after intervention ]
    Evaluation of the levels of neutralizing antibodies in every participant and the cellular immunity in a subgroup of subjects against the ancestral strain, the Omicron and Delta variants at 6 months after the administration of a booster dose of the Omicron, trivalent or CoronaVac® vaccines.


Other Outcome Measures:
  1. The humoral and cellular immunogenicity, in a subgroup of participants (homologous and heterologous groups), against new variants of concerns identified during the development of this trial. [ Time Frame: Up until 6 months after intervention ]
    The humoral and cellular immune response elicited against new variants of concerns identified during the development of this trial will be evaluated in a subgroup of participants (homologous and heterologous groups).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adults, male or female, over 18 years of age;
  • Fully vaccinated against SARS-CoV-2 with two initial doses of CoronaVac® vaccine and that have received two booster doses of a different vaccine (heterologous group) or with CoronaVac® (homologous group) at least 5 months before enrollment;
  • Capable of understanding and signing the informed consent form;
  • Availability and commitment to comply with study procedures and in-person and remote appointments.

Exclusion Criteria:

  • Symptomatic COVID-19 diagnosed 60 days before enrollment (confirmed COVID-19 by RT-PCR or antigen test, or by being in close contact with a confirmed case);
  • Pregnant women (confirmed by urine pack test) or women who plan to get pregnant within the first 3 months of the study;
  • Known allergies to the vaccine components;
  • Evidence of uncontrolled metabolic, neurologic#, cardiac, pulmonary, hepatic, or renal disease. Significant changes in medical treatment or hospitalizations due to worsening conditions in the last three months are indicators of uncontrolled disease or unsuccessful adherence to the treatment;
  • Alteration of the immune system (neoplasms, except basal cell cancer), congenital or acquired immunodeficiencies, and uncontrolled autoimmune diseases. Significant changes in medical treatment or hospitalizations due to worsening conditions in the last three months are indicators of uncontrolled disease;
  • Behavioral, psychiatric, or cognitive conditions# that, according to the study physician, impair the ability to understand and cooperate with the requirements of this trial;
  • Intake of immunosuppressants within 6 months before enrollment or prescribed to be taken within the next 2 years of the study. Antineoplastic therapy, radiation, and immunosuppressants that induce tolerance to transplants, among others, are included in this category;
  • Intake of corticosteroids within 3 months before enrollment or prescribed to be taken within 3 months after enrollment. The equivalent of 20 mg/day of prednisone for more than one week will be considered an immunosuppressive dose. Topical or inhaled steroids are not considered immunosuppressive drugs;
  • History of anatomic or functional asplenia;
  • Coagulation disorders such as coagulation factor deficiency, coagulopathy or platelet disorders, or a history of significant bleeding or bruising from intramuscular injections or venipunctures;
  • Alcohol or drug abuse reported 12 months before enrollment that caused medical, professional, or family consequences;
  • Have been treated with blood or immunoglobulin transfusions within 3 months before enrollment;
  • Have you received any live attenuated or inactivated vaccine within 28 and 14 days prior to the enrollment or planned to receive one within the first 28 days of the study;
  • Participation in another clinical trial 6 months before the enrollment or plan to participate in one 6 months after the enrollment in this trial;
  • Prior participation in a SARS-CoV-2 vaccine trial different than the CoronaVac03CL trial;
  • Any fever episode (body temperature ≥37.8℃) within 3 days before enrollment;

  • Any other condition that according to the primary care physician, could jeopardize the safety/rights of the subject or prevent him/her from completing the protocol

    • Alzheimer's and senile dementia are exclusion criteria.

Note: Obese and smoker participants are allowed to participate.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05593042


Contacts
Layout table for location contacts
Contact: Pablo A González, PhD +56982287536 pagonzalez@bio.puc.cl
Contact: Alexis M Kalergis, PhD +56981573949 akalergis@bio.puc.cl

Locations
Layout table for location information
Chile
Pontificia Universidad Católica - Marcoleta Center Recruiting
Santiago, Metropolitana, Chile
Contact: Pablo M González, PhD       pagonzalez@bio.puc.cl   
Universidad San Sebastián Recruiting
Santiago, Metropolitana, Chile
Contact: Pablo A González, PhD       pagonzalez@bio.puc.cl   
Universidad del Desarrollo - Clínica Alemana Recruiting
Santiago, RM, Chile
Contact: Pablo A González, PhD       pagonzalez@bio.puc.cl   
Sponsors and Collaborators
Pontificia Universidad Catolica de Chile
Sinovac Life Sciences Co., Ltd.
Investigators
Layout table for investigator information
Study Director: Pablo A Gonzalez, PhD Pontificia Universidad Catolica de Chile
Study Chair: Alexis M Kalergis, PhD Pontificia Universidad Catolica de Chile
Study Chair: Susan M Bueno, PhD Pontificia Universidad Catolica de Chile
Study Chair: Katia Abarca, MD Pontificia Universidad Catolica de Chile
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Pontificia Universidad Catolica de Chile
ClinicalTrials.gov Identifier: NCT05593042    
Other Study ID Numbers: PRO-tonCOV-2001-CL
First Posted: October 25, 2022    Key Record Dates
Last Update Posted: January 13, 2023
Last Verified: September 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Pontificia Universidad Catolica de Chile:
Clinical Trials
COVID-19
Inactivated Vaccine
Omicron Vaccine
Trivalent Vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
Infections
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
 Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs